Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 10:30 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
March 28, 2022 16:05 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

REHOVOT, Israel and WILMINGTON, Del., March 28, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Ayala or the Company) (Nasdaq: AYLA), a clinical-stage oncology company focused on...
March 09, 2022 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
March 08, 2022 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals, MD Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation Announce Initiation of Enrollment in Window of Opportunity Study of AL101 in Adenoid Cystic Carcinoma

REHOVOT, Israel and WILMINGTON, Del., March 08, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), together with M.D. Anderson Cancer Center and the Adenoid Cystic Carcinoma (ACC)...
February 23, 2022 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors

REHOVOT, Israel and WILMINGTON, Del., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
January 06, 2022 08:28 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
January 04, 2022 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Key Business Objectives for 2022

REHOVOT, Israel and WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing...
November 15, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

- Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 – - Presented Pre-Clinical Proof of Concept...
November 10, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
September 23, 2021 08:30 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

REHOVOT, Israel and WILMINGTON, Del., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...